Recently, Canaan Technology released the 2022 semi-annual report.
During the reporting period, the company achieved operating income of 494 million yuan, a year-on-year increase of 14.
33%, and realized a net profit attributable to shareholders of the listed company of 42.
36 million yuan, a year-on-year increase of 12.
63%.
The net profit of shareholders of the listed company after deducting non-recurring gains and losses was 39.
49 million yuan, a year-on-year increase of 19.
86%, and the basic earnings per share was 0.
09 yuan
.
A large number of pharmaceutical machine companies are accelerating their development towards diversification! (Image source: Pharmaceutical Network)
On the evening of August 29, Tofflon also released a semi-annual report showing that the company achieved operating income of 2.
427 billion yuan in the first half of this year, a year-on-year increase of 34.
11%; realized a net profit of 403 million yuan attributable to shareholders of listed companies, a year-on-year increase of 18.
33%; Deducted non-net profit of 371 million yuan, a year-on-year increase of 21.
28%
It is worth noting that in a number of corporate announcements, it is clearly stated that its performance growth is related to its past diversification and business expansion
.
Among them, Canaan Technology’s announcement shows that the increase in operating income is mainly due to the gradual expansion of sales scale and business expansion
.
It is understood that Canaan Technology's main business is pharmaceutical equipment, and it is a professional supplier of overall solutions for oral solid preparation smart factories in China
.
Since its listing, Canaan Technology has implemented the concept of full-chain in-depth service in the process of business development, established a relatively complete service system, and got rid of the traditional manufacturing enterprise that emphasizes production and ignores service, and is order-centric
.
During the reporting period, based on the big health industry, Canaan Technology further opened up the upstream and downstream industry chain of pharmaceutical equipment, and gradually developed from a pharmaceutical equipment supplier to a pharmaceutical company that provides process development, equipment procurement, project declaration and other pharmaceutical one-stop.
A comprehensive solution provider for services
.
By shifting the focus of operation from production to service, the company can not only expand its business, but also extend its business tentacles to service areas with greater profit margins, and can further build an industrial ecology, provide comprehensive services, and open up opportunities for the company's further development.
.
In addition, Tofflon also mentioned that during the reporting period, the company's pharmaceutical equipment product diversification and internationalization strategy achieved results, and the multi-field products such as injections, solid preparations, biological macromolecules, cells and genetic equipment steadily increased during the reporting period.
Benefiting from the global development trend and capacity construction of biomacromolecular drugs such as antibodies and vaccines, the company's biological stock solution related equipment has gained more domestic and foreign market opportunities, and the overall solution capability of biomacromolecule equipment has continued to improve
.
In addition to the above-mentioned companies, many pharmaceutical equipment companies are also opening up more growth space through diversified business layouts
.
The analysis believes that the diversified layout of pharmaceutical equipment companies is conducive to avoiding the situation of relying on a single business development and cultivating new growth points.
Therefore, diversified development will become one of the industry trends in the future
.
While many pharmaceutical equipment companies are accelerating their diversified development, a large number of companies will also usher in more new growth points
.
However, it should be noted that the diversified layout of pharmaceutical equipment companies will also face more and more challenges
.
For example, some pharmaceutical equipment companies have cross-border layouts in food, beverage and other fields.
There are many new and old players in these target fields, and corresponding brands have already occupied a certain market share in the Chinese market
.
After the pharmaceutical equipment companies enter the game, they will undoubtedly have a long way to go to break through the siege
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
,
